Skip to content


Closeup of a CT scan with brain

Cancer imaging

There are around 1,000 new cases of cancer every day in the UK (2016-2018). In Yorkshire in particular, people are more likely to get cancer and die from it than most other counties in England. We want to change this.

The health challenge

Comorbidities in patients with cancer are negatively associated with outcomes and survival rates. The sooner cancer is diagnosed and the more information we have about a patient's cancer, the higher the chance of finding the most effective treatment.

Our mission is to improve the availability and capabilities of nuclear imaging of cancer, allowing personalised treatments that would be most effective for patients.

We work in collaboration with the Clinical Sciences Centre and the Hull Molecular Imaging Centres (HuMIC), a group of state-of-the-art medical imaging research facilities that improve access to the best standard of diagnostic care for cancer patients.


Research leads

Dr Louis Allott

Lecturer in Translational Radiopharmaceutics


Cameron Newbould, PhD Researcher

Nicole Lawrence, PhD Researcher

Brandon O'Melia, PhD Researcher

Joseph Ercolano, PhD Researcher

Lucy Wisemen, PhD Researcher

Hull Molecular Imaging Centres (HuMIC)

Our cancer imaging research utilises three main facilities, generously funded by the Daisy Appeal Charity, University and NHS Trust:

  • PET Research Centre (PETRC) – University of Hull
  • Molecular Imaging Research Centre (MIRC) – Castle Hill Hospital, East Yorkshire
  • Jack Brignall PET-CT Centre – Castle Hill Hospital, East Yorkshire

We have access to world-class research facilities, from the development and production of research radiopharmaceuticals and in vitro / in vivo pre-clinical evaluation (PETRC), to good manufacturing practice clinical translation (MIRC) and in-human evaluation (Jack Brignall PET-CT Centre).

HuMIC is equipped with two cyclotrons across both PETRC and MIRC, producing fluorine-18 and carbon-11 on demand. In addition, we hold gallium-68 and technetium-99m generators, with established delivery routes for a wide range of isotopes, including zirconium-89, indium-111, iodine-124, copper-64 and 67 and lutetium-177.


We collaborate with a number of researchers at Hull York Medical School including in the Clinical Sciences Centre, the Hull Health Trials Unit, and the Academy of Primary Care, as well as the Chemistry Department at the University of Hull.

We also work with industry partners such as Invicro, ImaginAb, Novartis and Isogenica Ltd.

We are open to working with new partners in the development and evaluation of novel radiopharmaceuticals or drug development and welcome any enquiries. Please contact us at:


Biomedical Institute for Multimorbidity